Healthcare provider profile · identity verified

Manasvi Jaitly, MD

Internal Medicine · OGDENSBURG, NY · NPI 1205036878

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	626	174
Prosol	Parenteral Amino Acid 20% No.1	496	18
Jardiance	Empagliflozin	436	71
Furosemide	Furosemide	401	118
Losartan Potassium	Losartan Potassium	331	93
Lisinopril	Lisinopril	303	79
Irbesartan	Irbesartan	257	59
Doxazosin Mesylate	Doxazosin Mesylate	252	56
Atorvastatin Calcium	Atorvastatin Calcium	218	63
Metoprolol Succinate	Metoprolol Succinate	217	62
Allopurinol	Allopurinol	206	59
Rosuvastatin Calcium	Rosuvastatin Calcium	200	53
Hydralazine Hcl	Hydralazine Hcl	179	39
Potassium Chloride	Potassium Chloride	177	47
Carvedilol	Carvedilol	162	47
Spironolactone	Spironolactone	148	34
Labetalol Hcl	Labetalol Hcl	123	26
Chlorthalidone	Chlorthalidone	118	26
Atenolol	Atenolol	117	33
Torsemide	Torsemide	117	27
Nifedipine Er	Nifedipine	114	31
Gabapentin	Gabapentin	112	34
Pantoprazole Sodium	Pantoprazole Sodium	111	30
Hydrochlorothiazide	Hydrochlorothiazide	104	29
Terazosin Hcl	Terazosin Hcl	96	20
Famotidine	Famotidine	95	31
Farxiga	Dapagliflozin Propanediol	92	16
Clonidine Hcl	Clonidine Hcl	83	18
Omeprazole	Omeprazole	73	18
Calcitriol	Calcitriol	72	17
Metoprolol Tartrate	Metoprolol Tartrate	70	17
Sevelamer Carbonate	Sevelamer Carbonate	67	25
Clinisol	Parenteral Amino Acid 15% No.5	66	suppressed
Sertraline Hcl	Sertraline Hcl	64	12
Tamsulosin Hcl	Tamsulosin Hcl	64	21
Prednisone	Prednisone	62	29
Tradjenta	Linagliptin	62	12
Doxycycline Hyclate	Doxycycline Hyclate	53	37
Isosorbide Dinitrate	Isosorbide Dinitrate	51	12
Levothyroxine Sodium	Levothyroxine Sodium	51	17
Mirtazapine	Mirtazapine	50	11
Glimepiride	Glimepiride	46	11
Simvastatin	Simvastatin	44	suppressed
Eliquis	Apixaban	43	15
Calcium Acetate	Calcium Acetate	42	11
Glipizide Er	Glipizide	42	11
Esomeprazole Magnesium	Esomeprazole Magnesium	40	suppressed
Midodrine Hcl	Midodrine Hcl	39	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	38	33
Oxycodone Hcl	Oxycodone Hcl	37	11
Albuterol Sulfate Hfa	Albuterol Sulfate	36	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	36	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	35	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	suppressed
Veltassa	Patiromer Calcium Sorbitex	35	suppressed
Ezetimibe	Ezetimibe	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	34	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	11
Clopidogrel	Clopidogrel Bisulfate	32	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Cefdinir	Cefdinir	30	22
Triamcinolone Acetonide	Triamcinolone Acetonide	30	14
Lovastatin	Lovastatin	28	suppressed
Trazodone Hcl	Trazodone Hcl	28	suppressed
Enalapril Maleate	Enalapril Maleate	27	suppressed
Metformin Hcl	Metformin Hcl	27	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Febuxostat	Febuxostat	23	suppressed
Fluconazole	Fluconazole	23	16
Metoclopramide Hcl	Metoclopramide Hcl	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Potassium Citrate Er	Potassium Citrate	22	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	21	suppressed
Rybelsus	Semaglutide	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Bumetanide	Bumetanide	20	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	20	suppressed
Olanzapine	Olanzapine	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	19	suppressed
Ozempic	Semaglutide	19	suppressed
Entresto	Sacubitril/Valsartan	18	suppressed
Metolazone	Metolazone	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Xifaxan	Rifaximin	18	suppressed
Cephalexin	Cephalexin	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	12
Bisoprolol Fumarate	Bisoprolol Fumarate	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	15	11
Diltiazem 24hr Er (La)	Diltiazem Hcl	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Minoxidil	Minoxidil	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Nystatin	Nystatin	14	suppressed
Repatha Sureclick	Evolocumab	14	suppressed
Temazepam	Temazepam	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Dilt-Xr	Diltiazem Hcl	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Ramipril	Ramipril	13	suppressed
Carisoprodol	Carisoprodol	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Pitavastatin Calcium	Pitavastatin Calcium	12	suppressed
Prazosin Hcl	Prazosin Hcl	12	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Azithromycin	Azithromycin	11	11
Buspirone Hcl	Buspirone Hcl	11	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Praluent Pen	Alirocumab	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error